Moreover, P-NLC-Chi-siRNA significantly reduced the PD-L1 mRNA expression both in vitro and in vivo, leading to enhanced CD4+ and CD8+ T-cell responses, thereby augmenting the synergistic antitumor effect in tumor xenograft models. This evidence concerns the gene CD4 and neoplasm.